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Summary
PCXMC is a Monte Carlo program for calculating patients' organ doses and 
effective doses in medical x-ray examinations. The organs and tissues considered 
in the program are: active bone marrow, adrenals, brain, breasts, colon (upper and 
lower large intestine), extrathoracic airways, gall bladder, heart, kidneys, liver, 
lungs, lymph nodes, muscle, oesophagus, oral mucosa, ovaries, pancreas, prostate, 
salivary glands, skeleton, skin, small intestine, spleen, stomach, testicles, thymus, 
thyroid, urinary bladder and uterus. 
The program calculates the effective dose with both the present tissue weighting 
factors of ICRP Publication 103 (2007) and the old tissue weighting factors of 
ICRP Publication 60 (1991). The anatomical data are based on the mathematical 
hermaphrodite phantom models of Cristy and Eckerman (1987), which describe 
patients of six different ages: new-born, 1, 5, 10, 15-year-old and adult patients. 
Some changes are made to these phantoms in order to make them more realistic 
for external irradiation conditions and to enable the calculation of the effective 
dose according to the new ICRP Publication 103 tissue weighting factors. The 
phantom sizes are adjustable to mimic patients of an arbitrary weight and 
height. 
PCXMC allows a free adjustment of the x-ray beam projection and other 
examination conditions of projection radiography and fluoroscopy. All organ 
doses calculated by PCXMC are relative to the incident air kerma, Ka,i. This 
quantity represents the air kerma at the point where the central axis of the 
x-ray beam enters the patient. It is given in units of milligray (mGy), free-in-air, 
without backscatter; see ICRU 74 (2005). The user must supply this datum to the 
program. The amount of radiation can also be input as the entrance exposure (mR, 
free-in-air, without backscatter), air kerma-area product or dose-area product 
(mGy·cm2), or exposure-area product (R·cm2). If radiation measurements are not 
available, the program is able to estimate the incident air kerma also from an 
input of the x-ray tube current-time product (mAs).
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The dose calculation method in PCXMC is the Monte Carlo method. The Monte 
Carlo calculation of photon transport is based on stochastic mathematical 
simulation of interactions between photons and matter. Photons are emitted 
(in a fictitious mathematical sense) from a point source into the solid angle 
specified by the focal distance and the x-ray field dimensions, and followed 
while they randomly interact with the phantom according to the probability 
distributions of the physical processes that they may undergo: photo-electric 
absorption, coherent (Rayleigh) scattering or incoherent (Compton) scattering. 
At each interaction point the energy deposition to the organ at that position is 
calculated and stored for dose calculation. Other interactions are not considered 
in PCXMC because the maximum photon energy is limited to 150 keV. This 
chain of interactions forms a so-called history of an individual photon. A large 
number of independent photon histories is generated, and estimates of the mean 
values of energy depositions in the various organs of the phantom are used for 
calculating the doses in these organs. 
Calculated organ doses can be used for the assessment of the risk of exposure-
induced cancer. The risk estimates are based on the combined absolute and 
relative risk models of BEIR VII committee (BEIR 2006). PCXMC calculates 
the risk of exposure-induced death for leukaemia, cancers in colon, stomach, 
lung, urinary bladder, prostate, uterus, ovaries, breast, liver, thyroid and for all 
other solid cancers combined. The user may use the risk calculation module for 
estimating the cancer risk resulting from a single exposure or multiple exposures 
simulated in PCXMC. The user may also edit the organ doses without calculating 
doses with PCXMC: a radiation risk assessment can be made for arbitrary 
irradiation cases.
The present version (2.0) of the program runs in a PC under Windows 95/98/
NT/2000/XP/Vista. The Monte Carlo simulation time depends on the desired 
accuracy and on the speed of the PC, but is typically less than a minute in 
a PC with a 1.8 GHz processor. The same Monte Carlo data can be used for 
calculating doses for any x-ray spectrum of interest when the other conditions 
of the examination remain unchanged; in this case the calculation time is very 
short because no further Monte Carlo simulations are needed. 
The data calculated by PCXMC have been earlier compared to the organ dose 
conversion factors calculated in NRPB by Jones and Wall (1985) and Hart et al. 
(1994, 1996) and were found to agree well (Tapiovaara et al. 1997). The excellent 
agreement with the NRPB data still exists for most irradiation conditions. Small 
differences are noted in some irradiation conditions, because the composition 
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and density of the phantom tissues have been changed and the phantoms have 
been modified from the earlier versions of the program. Reasonable agreement of 
PCXMC results has also been found in many comparisons with dose measurements 
and calculations with other phantom models, e.g., Schmidt et al. (2000), Schultz 
et al. (2003), Helmrot et al. (2007). The usability of the phantom size modification 
feature of PCXMC has been demonstrated in an extreme case by Smans et al. 
(2008) who calculated doses in two premature babies with weights of 590 g and 
1910 g. The differences between the doses calculated with their voxel phantoms 
and PCXMC were explained by the differences in the phantom models and 
the difficulty to place an x-ray field in them in an equivalent fashion. Similar 
differences between computational and voxel phantoms have also been seen in 
the papers of Staton et al. (2003), Lee et al. (2006) and Pazik et al. (2007); dose 
differences of the same order are obtained also in dose calculations with different 
voxel phantoms (Zankl et al. 2002, Schlattl et al. 2007). 
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TAPIOVAARA Markku, SIISKONEN Teemu. PCXMC. Monte Carlo -ohjelma 
röntgentutkimuksista potilaalle aiheutuneiden annosten laskemiseksi. STUK-
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Tiivistelmä
PCXMC on lääketieteellisistä röntgentutkimuksista potilaille aiheutuneiden 
elinannosten ja efektiivisen annoksen laskentaan tarkoitettu Monte Carlo 
-ohjelma. Ohjelmassa tarkasteltuja elimiä ja kudoksia ovat: aivot, aktiivinen 
luuydin, eturauhanen, haima, iho, imusolmukkeet, kateenkorva, keuhkot, 
kilpirauhanen, kivekset, kohtu, lihakset, lisämunuaiset, luusto, mahalaukku, 
maksa, munasarjat, munuaiset, ohutsuoli, paksusuoli, perna, rinnat, rintakehän 
ulkopuoliset hengitystiet, ruokatorvi, sappirakko, suun limakalvot, sydän, 
sylkirauhaset ja virtsarakko. Nämä elimet ja kudokset tarvitaan ICRP:n nykyisen 
määritelmän mukaisen efektiivisen annoksen laskentaan.
Ohjelma laskee efektiivisen annoksen käyttäen sekä nykyisiä kudosten 
painotuskertoimia, jotka on annettu julkaisussa ICRP Publication 103 (2007), 
että aikaisempia kudosten painotuskertoimia, jotka on annettu julkaisussa ICRP 
Publication 60 (1991). Anatominen data perustuu Cristyn and Eckermanin (1987) 
matemaattisiin, hermafrodiittisiin ihmismalleihin (fantomeihin), jotka kuvaavat 
kuutta eri-ikäistä ihmistä: vastasyntynyttä, 1-, 5-, 10- ja 15-vuotiaita lapsia ja 
aikuista. Näihin fantomimalleihin on tehty joitakin muutoksia, jotta ne on saatu 
paremmin soveltuviksi ulkoisen säteilyaltistuksen arviointitilanteisiin ja jotta 
efektiivinen annos voitaisiin laskea ICRP 103 -julkaisun mukaisia kudosten 
painotuskertoimia käyttäen. Fantomien kokoa voidaan säätää, jotta ne saataisiin 
vastaamaan paremmin eripituisia ja -painoisia potilaita. 
PCXMC sallii kuvausprojektioiden ja muiden röntgenkuvaus- ja 
läpivalaisututkimusten parametrien vapaan käytön laskennassa. PCXMC 
laskee kaikki elinten annokset suhteessa säteilykeilassa potilaan ihon kohdalla 
mitattuun ilmakermaan (incident air kerma, Ka,i). Ohjelman käyttäjän on 
syötettävä tämä arvo ohjelmaan laskentaa varten: sen syöttäminen voidaan 
kuitenkin tehdä myös ilmaisemalla käytetyn säteilyn määrä säteilytyksen (X; 
mR), annoksen ja pinta-alan tulon (DAP; mGy∙cm2) tai säteilytyksen ja pinta-
alan tulon (R∙cm2) avulla. Mikäli säteilymittauksia ei ole käytettävissä, ohjelma 
kykenee arvioimaan kyseisen annoksen (Ka,i) myös putkivirran ja ajan tulosta 
(mAs). 
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PCXMC käyttää laskennassa Monte Carlo -menetelmää, jossa fotonien ja aineen 
välisiä vuorovaikutuksia simuloidaan stokastisesti. Fotoneita emittoidaan 
röntgenputken fokuspisteestä avaruuskulmaan, joka määräytyy fokusetäisyyden 
ja säteilyn kenttäkoon mukaisesti. Fotoneita seurataan, kun ne vuorovaikuttavat 
fantomissa satunnaisesti niille mahdollisten vuorovaikutusprosessien 
todennäköisyysjakaumien mukaisesti. Tällaisia vuorovaikutuksia ovat 
valosähköinen absorptio, koherentti (Rayleigh)sironta ja epäkoherentti 
(Compton)sironta. PCXMC:ssä ei käsitellä muita vuorovaikutustyyppejä, 
koska maksimifotonienergia on laskennassa rajattu arvoon 150 keV. Kussakin 
vuorovaikutuksessa tallennetaan luovutettu energia sille elimelle, missä 
vuorovaikutus tapahtuu. Kunkin fotonin vuorovaikutustapahtumat muodostavat 
ns. yksittäisen fotonin historian. Laskennassa generoidaan suuri määrä 
yksittäisten fotonien historioita, joista arvioidaan eri elimiin absorboituneiden 
energioiden odotusarvot, joista saadaan elinten annokset.  
Laskettuja elinten annoksia voidaan käyttää arvioimaan säteilystä aiheutuvaa 
syöpäkuoleman riskiä. Riskiarviot perustuvat BEIR VII -komitean (BEIR 
2006) kehittämien suhteellisen ja absoluuttisen riskimallin yhdistelmään. 
PCXMC arvioi säteilyn aiheuttaman kuoleman riskin leukemialle, paksusuolen 
syövälle, mahasyövälle, keuhkosyövälle, virtsarakon syövälle, eturauhasen 
syövälle, kohtusyövälle, munasarjasyövälle, rintasyövälle, maksasyövälle ja 
kilpirauhassyövälle sekä tekee yhteisarvion muille syöville. Ohjelman käyttäjä 
voi käyttää riskinlaskentaosiota arvioon, jossa tarkastellaan joko yhden kuvan tai 
useasta kuvasta koostuvan röntgentutkimuksen aiheuttamaa riskiä, kun elinten 
annokset on arvioitu PCXMC:n avulla. Ohjelman käyttäjä voi myös asettaa 
elinannokset haluamikseen, laskematta niitä PCXMC:n avulla: riskilaskenta 
voidaan tehdä mielivaltaiselle säteilyaltistustilanteelle. 
Ohjelman nykyinen versio (2.0) toimii PC-tietokoneessa, jossa on 
käyttöjärjestelmänä Windows 95, 98, NT, 2000, XP tai Vista. Monte Carlo 
-laskentaan kuluva aika riippuu laskennassa halutusta tarkkuudesta ja PC:n 
nopeudesta, mutta on tyypillisesti alle minuutin, kun käytetään PC:tä, jonka 
kellotaajuus on 1.8 GHz. Samaa Monte Carlo -laskennasta saatua dataa voidaan 
käyttää laskettaessa toisen röntgensäteilyspektrin tai säteilymäärän aiheuttamia 
annoksia, kunhan muut röntgentutkimukseen liittyvät tekijät pysyvät samoina. 
Tällaisten erilaisten altistusten laskenta-ajat ovat erittäin pienet, koska niiden 
laskentaan ei tarvita uutta Monte Carlo -simulointia. 
 PCXMC:n avulla laskettuja tuloksia on jo aiemmin verrattu Jonesin ja Wallin 
(1985) ja Hartin ym. (1994, 1996) NRPB:ssä laskemiin annosmuuntokertoimiin, 
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ja niiden on todettu vastaavan toisiaan hyvin (Tapiovaara ym. 1997). Tämä 
hyvä yhteensopivuus NRPB:n datan kanssa on edelleen voimassa valtaosalle 
röntgenkuvaustilanteita. Joissakin tilanteissa havaitaan nyt kuitenkin pienehköjä 
eroja, koska laskennassa käytettyjen fantomien muotoa, kudosten koostumusta 
ja tiheyttä on muutettu ohjelman aikaisemmista versioista. PCXMC:n 
tulokset ovat vastanneet kohtuullisen hyvin myös monien muiden mittausten 
ja laskentamallien tuloksia, esim. Schmidt ym. (2000), Schultz ym. (2003), 
Helmrot ym. (2007). PCXMC:n fantomien kokomuunnoksen käyttökelpoisuus 
myös ääritilanteessa on todettu Smansin ym. (2008) julkaisemassa artikkelissa, 
jossa laskettiin kahden erikokoisen keskoslapsen (590 g ja 1910 g) annoksia. 
Heidän vokselifantomeillaan laskettujen annosten erot PCXMC:llä laskettuihin 
annoksiin selittyivät fantomimallien eroilla ja vaikeudella kohdistaa samanlainen 
säteilykeila erilaisiin fantomeihin niin, että altistustilanteet olisivat tarkasti 
vertailukelpoiset. Samansuuruisia eroja nähdään yleisesti, kun verrataan 
matemaattisten fantomien ja vokselifantomien avulla laskettuja annoksia (Staton 
ym. 2003, Lee ym. 2006 ja Pazik ym. 2007); samansuuruisia eroja saadaan myös, 
kun verrataan annoslaskuja, joissa on käytetty erilaisia vokselifantomeita (Zankl 
ym. 2002, Schlattl ym. 2007). Riskiarviotulokset ovat sopusoinnussa BEIR VII 
-komitean (BEIR 2006) raportissa annettujen arvojen kanssa.
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1 Introduction
X-ray diagnostics is a significant source of radiation exposure among the 
population. Therefore, it is important that x-ray examinations are conducted 
using techniques that keep the patients' exposure as low as possible but still 
compatible with the medical purposes of the examinations (ICRP 1996). In order 
to achieve this, it is necessary to understand the factors that affect the exposure 
and to be able to assess the patients' doses. 
Patient dose is often described by the patient’s entrance surface dose, which 
is measured on the patient’s skin at the centre of the x-ray beam. An alternative 
to this is to make the measurement free-in-air, without the contribution of 
the radiation that is backscattered from the patient, and express the result in 
terms of air kerma (incident air kerma, ICRU 2005). In some cases such simple 
measurements may be sufficient. This is the case, for example, in quality control 
measurements which concern the stability of equipment, and where the same 
x-ray exposure conditions are used in each measurement. However, the entrance 
surface dose is not sufficient for comparison or assessment of patients’ doses if the 
irradiation conditions (the size of the patient, the radiation quality, the exposed 
body-part, or other factors) are changed. In such cases, the patient dose needs 
to be characterised by quantities that are more directly related to the detriment 
caused by radiation (ICRU 2005). Optimisation of imaging techniques is an 
example of a case where the incident air kerma or the entrance surface dose are 
not sufficient for quantifying the patient dose, unless the local skin dose –not 
cancer induction– is the primary concern.
Presently, stochastic harm to humans from ionising radiation is assessed 
by the mean absorbed doses (or equivalent doses) in various organs or tissues 
in the body (ICRP 2007). For some purposes, the detriment can be assessed – 
and reported more simply– by referring to the effective dose: this enables one to 
express the dose as a single number, instead of a list of doses in various organs 
and tissues. However, the use of the effective dose in describing the radiation 
exposure of patients is sometimes criticized and it is suggested that appropriate 
risk values for the individual tissues at risk should be used instead (ICRP 2007). 
Therefore, also the ability of assessing the risk of exposure-induced cancer has 
been built to PCXMC 2.0. The risk assessment is done according to the model of 
BEIR VII Committee (BEIR 2006). 
Organ doses and the effective dose cannot be measured directly in patients 
undergoing x-ray examinations, and they are difficult and time consuming to 
obtain by experimental measurements using physical phantoms. However, they 
can be calculated to a reasonable approximation, provided that sufficient data 
on the x-ray examination technique are available. Today, such calculations are 
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most often made using the Monte Carlo calculation method, where random 
numbers are used for simulating the transport of radiation in a complex medium, 
in this case the human body. [For references on the Monte Carlo method in 
medical applications, see, for example, Andreo (1991).] The physical interactions 
between radiation and matter are sufficiently well-known, and the accuracy of 
the calculation is limited mainly by the accuracy of the anatomical model used 
to describe actual patients and by the characterisation of the applied radiation 
field (Zankl et al. 1989, Jones and Wall 1985). 
Monte Carlo data on organ doses and the effective dose in general projection 
radiography of adults have been presented in tabular form in Rosenstein (1976a 
and 1976b), Rosenstein et al. (1992), Jones and Wall (1985), Drexler et al. (1990), 
Hart et al. (1994a and 1994b) and Stern et al. (1995). Similar data for children 
have been presented in Rosenstein et al. (1979), Zankl et al. (1989) and Hart et 
al. (1996a and 1996b). Such data and the methods for obtaining them have been 
reviewed in ICRU Report 74 (2005). Recently, Kramer et al (2008) have published 
a computer program which contains, among other data, conversion coefficients 
for 34 x-ray projections and 40 x-ray spectra; their conversion coefficients have 
been calculated using voxel-based adult male and female phantoms. In addition 
to these tabulated conversion factors, several publications consider special cases 
of x-ray examinations and give dose conversion factors for them.  In spite of the 
extensive tabulation of organ dose conversion factors in the above-mentioned 
references, not all x-ray projections or x-ray spectra of interest are covered and 
the data apply only for those individuals whose size and body-build correspond 
to the phantoms used in deriving the data. 
Radiation and Nuclear Safety Authority, Finland (STUK) first published 
PCXMC (PC program for X-ray Monte Carlo) in 1997 (Tapiovaara et al. 1997). 
This program allowed computation of organ doses for patients of different ages 
and sizes in freely adjustable x-ray projections and other examination conditions 
that are used in projection radiography and fluoroscopy. Since 1997, the program 
has been improved in several occasions. PCXMC versions 1.0–1.5 used slightly 
modified mathematical phantom models of Cristy (1980). In the present version 
(PCXMC 2.0) the phantom is still basically the same, but has been updated to the 
phantom models of Cristy and Eckerman (1987) with some further modifications 
(modification of the head, correction of some apparent errors in the data of Cristy 
and Eckerman and inclusion of some new organs: extrathoracic airways, oral 
mucosa, prostate and salivary glands). These modifications of the phantom enable 
the calculation of the effective dose using the tissue weighting factors introduced 
in ICRP Publication 103 (2007). The program is now also able to assess age- and 
sex-dependent radiation risks.
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The Monte Carlo simulation time depends on the desired accuracy and on 
the speed of the PC, but takes typically from a few seconds to a few minutes with 
a PC with a 1.8 GHz processor. After having made the Monte Carlo calculation 
once, the user can calculate the organ doses for various x-ray spectra with a 
minimal computation time.
14
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2 Radiation dose quantities in PCXMC
All organ doses calculated with PCXMC are given in proportion to the incident 
air kerma (Ka,i) which is measured free-in-air, without backscatter, at the point 
where the central axis of the x-ray beam enters the patient. The incident air 
kerma – or, alternatively, the exposure (X; in mR), the air kerma-area product 
(PKA, KAP or DAP; in mGy∙cm
2) or the exposure-area product (in R∙cm2) – must 
be supplied by the user of the program. This datum can be calculated from the 
technique factors [x-ray tube voltage (kV), tube current-time product (mAs), 
total filtration and focal spot-to-skin distance (FSD)] and measured data of the 
radiation output of the x-ray source, or it can be obtained from entrance surface 
air kerma measurements or DAP measurements of actual patient examinations. 
If no actual radiation measurements are available, one can use the ability of 
PCXMC to estimate Ka,i with a reasonable accuracy from the x-ray tube current-
time product (mAs); the other necessary parameters [the x-ray tube voltage (kV), 
the total filtration in the radiation beam and the distance from the x-ray tube 
focal spot to the patient’s skin (FSD)] must anyway be input by the user. 
If the entrance surface air kerma (Ka,e) or the entrance surface dose (ESD) 
at the centre of the x-ray beam has been measured on the patient's skin and 
includes radiation back-scattered from the patient, the dose must be divided by 
the backscatter factor (BSF) before using it in PCXMC. The BSF depends on the 
x-ray spectrum and beam size and is typically of the order of 1.3–1.4. The practical 
range of BSF is 1.1–1.6. For data on the BSF, see, for example, Grosswendt (1990), 
Petoussi-Henss et al. (1998) or ICRU (2005); some typical BSF values (Petoussi-
Henss et al. 1998) are shown in Table I. 
15
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Table I. Backscatter factors (BSF) for three field sizes and some x-ray spectra  typical 
in diagnostic  radiology.  (FSD 100  cm,  ICRU phantom  tissue.)  (Petoussi-Henss et  al. 
1998).
X-ray 
tube 
voltage
(kV)
Filtration HVL
(mm Al)
BSF
10×10 cm2 20×20 cm2 25×25 cm2
50 2.5 mm Al 1.74 1.25 1.27 1.28
60 2.5 mm Al 2.08 1.28 1.32 1.32
70 2.5 mm Al 2.41 1.31 1.36 1.36
70 3.0 mm A+0.1 mm Cu 3.96 1.39 1.47 1.47
80 2.5 mm Al 2.78 1.33 1.39 1.39
80 3.0 mm A+0.1 mm Cu 4.55 1.40 1.50 1.51
90 2.5 mm Al 3.17 1.34 1.41 1.42
90 3.0 mm A+0.1 mm Cu 5.12 1.41 1.51 1.53
100 2.5 mm Al 3.24 1.34 1.41 1.42
100 3.0 mm A+0.1 mm Cu 5.65 1.42 1.53 1.55
110 2.5 mm Al 3.59 1.35 1.43 1.44
120 3.0 mm A+0.1 mm Cu 6.62 1.42 1.54 1.56
130 2.5 mm Al 4.32 1.36 1.45 1.47
150 2.5 mm Al 4.79 1.36 1.46 1.48
150 3.0 mm A+0.1 mm Cu 8.50 1.41 1.54 1.57
If the patient’s entrance dose has been measured in terms of tissue dose instead 
of air kerma, the measured datum must be converted to air kerma before using it 
as an input to the program. Strictly, the conversion from tissue dose, Dtissue, to air 
kerma, Ka, depends on the composition of the tissue and the energy spectrum of 
radiation. For the energies of diagnostic radiology, the approximate relationship 
Ka = 0.94∙Dsoft tissue can be used. In the photon energy range considered in PCXMC 
(photon energies less than 150 keV), kerma in tissue and absorbed dose in tissue 
can be considered equivalent (except in bone-soft tissue interfaces, see chapter 
4 below).
PCXMC calculates the mean values of absorbed doses, averaged over the 
organ volume, for the organs shown in Table II1). In addition to these organ doses, 
the program calculates the effective dose for both the present tissue weighting 
factors wT (ICRP 2007) and the old ones (ICRP 1991)
2). PCXMC also calculates 
the average absorbed dose in the whole body, and the fraction of the x-ray beam 
energy that is absorbed in the phantom. In PCXMC, all absorbed doses (and 
air kerma) are in milligray (mGy). For photons, the numerical values of the 
1) In order to avoid ambiguity, it is noted that in PCXMC 'skin dose' refers to the mean value of 
absorbed dose averaged over the whole skin of the phantom.
2) For later modifications of this ‘old effective dose’ as used in PCXMC see, e.g., ICRP (1995)
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equivalent doses of organs in millisieverts (mSv) are equal to the corresponding 
organ doses in mGy. The unit of the effective dose is mSv.
In PCXMC the calculation of effective dose is not strictly done according 
to the specifications in ICRP Publication 103 (2007): in PCXMC, the effective 
dose is calculated using size-adjustable hermaphrodite phantoms, whereas the 
present ICRP (2007) definition specifies that the organ doses are calculated in a 
reference male phantom and in a reference female phantom, the equivalent organ 
doses in these two phantoms are averaged, and the effective dose is obtained 
as a weighted sum of these sex-averaged organ doses. This prescription cannot 
be easily followed in partial body exposures, such as x-ray imaging, where the 
field size and the quality and amount of radiation are adjusted according to the 
patient’s size: an x-ray beam of specified size cannot be unambiguously directed 
similarly to two phantoms of different size and shape. This difficulty is avoided 
by using hermaphrodite phantoms.  
The effective dose has been introduced to express a radiation detriment-
related dose for radiation protection purposes in situations where the dose to 
the body is not uniform and the absorbed doses are low enough for avoiding 
deterministic radiation effects. The effective dose is given as a weighted average 
of the equivalent doses in various organs and tissues. In deriving the tissue 
weighting factors, an equal number of males and females and a wide range of 
ages in the exposed population were assumed. Therefore, and because of the 
health status difference of patients and general population, it may not always 
be reasonable to use this quantity in reporting doses from medical radiology; for 
critical views on the use of the effective dose in diagnostic radiology see Drexler 
et al. (1993) and Martin (2007). If the patient material considered differs greatly 
from the average population, the use of a different set of weighting factors and 
risk coefficients should be more appropriate (BEIR 1990, Stokell et al. 1993, 
Almén and Mattsson 1996). Such age- and sex-dependent weighting factors have 
not been agreed on; therefore, for example the ICRP uses the same set of tissue 
weighting factors for all ages and even for the developing foetus, although with 
caution (ICRP 2007). 
The ICRP specifically stresses that effective dose should not be used for, 
e.g., the assessment of individual risk, assessment of the probability of causation 
of cancer, or for epidemiological studies. Absorbed doses to irradiated tissues 
should be used for these purposes. However, the ICRP acknowledges that the 
effective dose can be of value for comparing doses from different diagnostic 
procedures and for comparing the use of similar technologies and procedures in 
different hospitals and countries as well as the use of different technologies for 
the same medical examination (ICRP 2007). Effective dose has widely been used 
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for such purposes: for example in assessing the population dose from diagnostic 
x-ray examinations (e.g., UNSCEAR 2000, Hart and Wall 2002 and Scanff et al. 
2008). 
It should also be kept in mind that in partial body exposures local absorbed 
doses may be large even if the mean doses in organs or the effective dose are 
small. Therefore, low organ doses or a low effective dose do not necessarily imply 
avoiding deterministic radiation effects (tissue reactions) (ICRP 2007). 
PCXMC calculates the effective dose for allowing easy comparisons e.g. 
between different diagnostic procedures. If a more detailed risk assessment is 
needed, the risk calculation capability of PCXMC should be used. This risk model 
is based on the report of BEIR VII committee (BEIR 2006), and takes into account, 
e.g., the sex, age at exposure and attained age of the patient (see chapter 6 for 
more details). Still, it has to be remembered that individual risk estimates are 
highly uncertain because of inherent uncertainties in the risk models, the health 
status of the individual in question and, e.g. individual sensitivity to radiation-
induced cancer.
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Table II. The organs  considered  in PCXMC,  and  their  tissue weighting  factors  for 
the calculation of the effective dose according to both the present and the old ICRP 
definitions.
Organ or tissue Tissue weighting 
factor wT (ICRP 103) 
7)
Tissue weighting factor
wT (ICRP 60) 
8)
Active bone marrow 0.12 0.12
Breasts 0.12 0.05
Colon1) 0.12 0.12
Lungs 0.12 0.12
Stomach 0.12 0.12
Ovaries (female gonads)2) 0.08/2 0.20/2
Testicles (male gonads)2) 0.08/2 0.20/2
Liver 0.04 0.05
Oesophagus 0.04 0.05
Thyroid 0.04 0.05
Urinary bladder 0.04 0.05
Brain 0.01 r 
Bone surface3) 0.01 0.01
Salivary glands 0.01 - 
Skin 0.01 0.01
Adrenals 0.12/13 r
Extrathoracic airways4) 0.12/13 r
Gall bladder 0.12/13 -
Heart 0.12/13 -
Kidneys 0.12/13 r
Lymphatic nodes5) 0.12/13 -
Muscle6) 0.12/13 r
Oral mucosa 0.12/13 -
Pancreas 0.12/13 r
Prostate (male) 0.12/26 -
Small intestine 0.12/13 r
Spleen 0.12/13 r
Thymus 0.12/13 r
Uterus (female) 0.12/26 r
1)  The dose in the colon is calculated as the mass-weighted average 
of the upper large intestine and the lower large intestine.
2)  The dose in the gonads is defined as the average of the doses in the 
ovaries and testicles. The tissue weighting factor for gonads is presently 
0.08 (ICRP Publication 103) and was earlier 0.20 (ICRP Publication 60). 
3) The tissue weighting factor refers to the dose to bone surface. PCXMC approximates 
this dose using the dose to the whole skeleton (excluding active bone marrow). 
4) In PCXMC only the trachea, pharynx and nasal sinuses are 
used to represent the extrathoracic airways.
5) In PCXMC the lymph nodes have not been modelled in the phantom. The dose in lymph 
nodes is calculated as a weighted average of several surrogate organs (see chapter 3).
6) In PCXMC, the dose in muscle tissue is calculated as the average dose to the 
whole phantom, but excluding the other organs and tissues given in this table.
7) The weighting factors that are shown as the fraction 0.12/13 or 0.12/26 represent the 
remainder organs of ICRP 103. The new weighting factor for the arithmetic average 
of the remainder organs is given the tissue weighting factor 0.12. Sex-specific 
organs have effectively a lower weighting factor than the other remainder organs.  
8) Weighting factors labelled as “–” denote organs that are not included in the 
calculation of the effective dose according to the old ICRP 60 definition. Weighting 
factors labelled as “r” belong to the 'remainder tissues' of ICRP Publication 60. 
The tissue weighting factor of the ICRP 60 remainder is 0.05, and is applied to the 
mass averaged dose in the remainder organs and tissues. However, if any of these 
organs receives a dose that is higher than the dose to any of the twelve organs for 
which a weighting factor is specified, a weighting factor of 0.025 is applied to that 
tissue or organ and the rest of the weighting factor, 0.025, is applied to the mass 
averaged dose in the other remainder organs and tissues (ICRP 1991 and 1995).
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2.1 Incident air kerma calculation based on 
the tube current-time product (mAs)
PCXMC can evaluate the incident air kerma from the specified examination 
factors, when only the tube current-time product (mAs) is known. All other data 
needed for the evaluation: x-ray tube voltage (kV), total filtration and FSD, must 
be specified in the examination's input data anyway. This option cannot be used, 
if the user has specified the FSD to be infinite (actually: 100 m). 
In practice, the x-ray tube output varies from one unit to the next, however, 
and one cannot expect an exact agreement between the calculated and measured 
incident air kerma. Variability between x-ray tubes is caused at least by differences 
in the following factors:
•	 x-ray	 tube	 voltage	waveform	 (PCXMC	assumes	 a	 constant	 potential	 or	
low-ripple generator)
•	 x-ray	tube	anode	angle	 (not	used	 in	the	 incident	air	kerma	calculation	 in	
PCXMC)
•	 smoothness	of	the	x-ray	tube	anode	surface
•	 actual	 filter	materials	 in	 the	beam	path;	 [in	 spite	 of	matching	 filtration	
equivalence, the attenuation of the actual filter (including glass and oil) may 
differ from the attenuation of an aluminium filter]
•	 differences	in	off-focal	radiation	and	its	removal	by	collimation
•	 the	error	between	actual	and	displayed	values	of	the	tube	voltage	(kV),	the	
tube current-time product (mAs) and the filtration.
The x-ray tube output calculation of PCXMC is based on x-ray tube output 
measurements from diagnostic x-ray tubes. The basic data have been obtained from 
46 different x-ray tubes and/or filter choices. The average of these measurements 
agrees with the value calculated with PCXMC, and the standard deviation 
between the individual measured results and the calculated results is 16%. 
Therefore, one can expect the calculated output dose to be within about 30% (2 
standard errors) of the correct value. 
The ratio of calculated and measured results is typically constant for a 
given x-ray tube; the ratio typically stays the same although x-ray tube voltage or 
filtration is varied. This can be used to improve the accuracy of mAs-based dose 
calculations. By making x-ray tube output measurements for a given x-ray system 
and comparing these with the output values calculated by PCXMC one will get 
an effective 'mAs calibration coefficient' for that x-ray tube, and it can be used at 
all x-ray tube voltages and filter choices. By doing such a normalisation for each 
of the 46 x-ray tubes above, the standard deviation between individual measured 
and calculated results dropped to 5%, and the accuracy of the calculation can 
then be taken as 10%.
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3 Mathematical phantoms
Several phantom models are available for representing the human body in Monte 
Carlo calculations (e.g., Kramer et al. 1982, Cristy and Eckerman 1987, ICRU 
1992a, Lee et al. 2006a, Schlattl et al. 2007). These include voxel-phantoms, which 
are based on CT and MR images of actual human beings, and computational models 
where body contours and organs are defined by mathematical expressions. 
The phantoms used in PCXMC version 2.0 are computational hermaphrodite 
phantoms representing human beings of various ages (new-born, 1, 5, 10, 
15-year-old and adult). These phantoms have been specified by Cristy and 
Eckerman (1987), but a few modifications, explained below, have been made in 
PCXMC. The principal body dimensions of these phantoms are given in Table III, 
and the composition of their tissues is shown in Table IV. The phantom models 
used in earlier versions of PCXMC were somewhat different: they were modelled 
according to Cristy (1980) with small modifications (Tapiovaara et al. 1997).
Table III. Principal dimensions of the mathematical phantoms as modified in PCXMC 2.0. 
In the calculation the user can specify whether the arms of the phantom are included at 
the sides of the trunk or whether they are removed (which may simulate the real situation 
better, e.g., for lateral projections). Trunk width is given for both of these conditions. 
Phantom height and weight have changed from the earlier PCXMC versions.
Weight
(kg)
Total height
(cm)
Trunk
height
(cm)
Trunk 
thickness
(cm)
Trunk
width1)
(cm)
Trunk
width2)
(cm)
Leg
length
(cm)
Newborn 3.40 50.9 21.6 9.8 10.94 12.7 16.8
1 year old 9.20 74.4 30.7 13.0 15.12 17.6 26.5
5 year old 19.0 109.1 40.8 15.0 19.64 22.9 48.0
10 year old 32.4 139.8 50.8 16.8 23.84 27.8 66.0
15 year old 56.3 168.1 63.1 19.6 29.66 34.5 78.0
Adult 73.2 178.6 70.0 20.0 34.40 40.0 80.0
1)  excluding arms
2)  including arms
Table IV. Elemental composition of the phantom tissues as used in PCXMC 2.0 (% by 
weight). The number of elements has been reduced from that in Cristy and Eckerman 
(1987) by grouping the elements Na, Mg, P, S, and Cl together and treating them as 
phosphorus, and grouping all elements of atomic numbers from that of K or higher 
together and treating them as calcium. The density and composition have changed from 
the earlier PCXMC versions.
Density
(g/cm3)
H
(%)
C
(%)
N
(%)
O
(%)
P
(%)
Ca
(%)
Skeleton (except newborn) 1.40 7.337 25.475 3.057 47.893 5.876 10.362
Newborn skeleton 1.22 7.995 9.708 2.712 66.811 4.623 8.151
Lung tissue 0.296 10.134 10.238 2.866 75.752 0.770 0.240
Other soft tissues 
(except newborn)
1.04 10.454 22.663 2.490 63.525 0.626 0.242
Other soft tissues 
(newborn)
1.04 10.625 14.964 1.681 71.830 0.592 0.308
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The phantom models of Cristy and Eckerman (1987) were intended to be used 
for dosimetry of internal photon sources. After their publication, the head and 
neck region and the upper part of the spine of the phantoms have been modified 
by Eckerman and Ryman (1993) in order to have the phantom models better 
suited for external irradiation calculations. These modifications are explained 
in more detail in Eckerman, Cristy and Ryman (1996). Eckerman and Ryman 
(1993) also added the oesophagus among the organs in the phantoms. These 
modifications have also been included in PCXMC 2.0, although with small 
further modifications: 
•	 The	back	of	the	head	has	been	modelled	as	a	circular	cone,	rather	than	as	an	
elliptic cylinder as in Eckerman, Cristy and Ryman (1996). For an example of 
the old and new head and neck area, see Figure 1. The head model of PCXMC 
resembles, but is not equal to, the MIRD head model (Bouchet et al. 1999). 
•	 The	 lateral	width	 of	 the	 facial	 skeleton	has	been	 reduced	 from	 the	value	
given in Cristy and Eckerman (1987) in order to make room for the parotid 
glands.
•	 The	apparent	error	in	the	vertical	location	of	the	facial	skeleton	in	the	data	
of Eckerman, Cristy and Ryman (1996) has been corrected, and the facial 
skeleton is located in a lower position than where it would be according to 
their data.
•	 The	apparent	error	in	the	position	of	the	thyroid	in	the	data	of	Eckerman,	
Cristy and Ryman (1996) has been corrected. The data used in PCXMC for 
the adult phantom corresponds to the data given in Eckerman and Ryman 
(1993).
•	 Salivary	glands	(parotid,	sublingual	and	submandibular	glands)	have	been	
modelled in the phantoms. The size and location of the glands were derived 
from data in ICRP Publication 89 (ICRP 2002) and Möller and Reif (1994a).
•	 Extrathoracic	airways	(pharynx,	larynx,	part	of	trachea,	paranasal	sinuses)	
have been modelled in the phantoms. Guidance for the modelling was obtained 
from Möller and Reif (1994a). Mouth has not been considered as a part of 
extrathoracic airways, although it is among the extrathoracic airway tissues 
mentioned in ICRP Publication 89 (ICRP 2002). Mouth mucosa is treated 
separately in PCXMC.
•	 Mouth	mucosa	has	been	modelled	in	the	phantoms.	Part	of	the	tissue	is	located	
between the skin and the facial skeleton, and another part behind the facial 
skeleton.
•	 The	prostate	has	been	modelled	in	the	phantoms.	Guidance	for	the	modelling	
was obtained from ICRP Publication 89 (ICRP 2002) and Möller and Reif 
(1994b).
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•	 The	arms	of	the	phantoms	can	be	removed	in	order	to	enable	more	realistic	
calculations for lateral x-ray projections. When the user chooses this option, 
it is realised by cutting the trunk region with two planes, which are parallel 
to the y-z plane, and located at the maximum dimension of the rib cage in the 
direction of the x-axis, but increased by the thickness of the skin. (The origin 
of the coordinate system is located at the middle of the base of the trunk of 
each phantom; the z-axis points upwards, the x-axis to the left-hand side of 
the phantom, and the phantom looks in the negative y-direction.)
•	 The	height	and	mass	of	the	phantoms	can	be	varied	and	matched	to	the	data	
of individual patients. This feature is explained in more detail below.
•	 Lymph	nodes	have	not	been	modelled	in	the	phantoms.	Instead,	the	dose	in	
the lymph nodes is estimated from the doses in surrogate organs as
Dlymph nodes = 0.25∙Dsmall intestines + 0.15∙Dpancreas +
 0.13∙Dextrathoracic airways + 0.10∙Dgall bladder +
 0.08∙Dsalivary glands + 0.07∙Dlungs + (1)
 0.05∙Dthyroid + 0.05∙Dtotal body +
 0.04∙Doesophagus + 0.04∙Dheart +
 0.03∙Dstomach + 0.01∙Dtestes .
These surrogate organs and the weights in the averaging have been chosen with 
the guidance of the data given in qatarneh et al. (2006), Möller and Reif (1994a 
and 1994b) and ICRP Publication 89 (ICRP 2002).
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(a) (b)
Figure 1. An example of the head and neck area of the adult phantom, displayed with the 
“radiograph”-image in (a) PCXMC 2.0 (new model), (b) PCXMC 1.5 (modelled according 
to Cristy 1980). The head and neck model  in  the new version  (2.0)  is notably more 
appropriate for external irradiation dose calculations. The model of Eckerman, Cristy 
and Ryman (1993) would be in between these two models and would have excess soft 
tissue material at the back of the head: their head model is an elliptical cylinder topped 
by half an ellipsoid. The skeleton is shown in white, the thyroid in pink, the airways 
in blue, and the oesophagus in yellow colour. (Colours are seen only in the electronic 
document version.)
(a) (b) (c) (d) (e) (f)
Figure 2. Anterior views of the basic phantom models in PCXMC, scaled to have identical 
heights. (a) Adult phantom 178.6 cm/73.2 kg, (b) 15-year old phantom 168.1 cm/56.3 kg, 
(c) 10-year old phantom 139.8 cm/32.4 kg, (d) 5-year old phantom 109.1 cm/19.0 kg, (e) 
1-year old  phantom 74.4 cm/9.2 kg (f) new-born phantom 50.9 cm/3.4 kg.
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Figure 2 illustrates the exterior shapes of the basic phantom models. PCXMC 
allows further modification of these basic phantoms by letting the user change 
the mass (M) or height (h) of any of them. Using these target body size values, 
the program calculates the scaling factors
(2)
and
(3)
where sz is the scaling factor in the direction of the z-axis (phantom height), 
sxy the scaling factor in the directions of the x- and y-axes (phantom width and 
thickness, respectively), and h0 and M0 are the height and weight of the unscaled 
phantom (Table III). All dimensions of the phantoms are then multiplied by these 
scaling factors, and the organ masses are changed accordingly. The coordinates 
corresponding to the transformed phantom, (x, y, z), are obtained from the 
coordinates of the same anatomical point corresponding to the basic phantom, 
(xo, yo, zo), by
 x = sxy xo 
 y = sxy yo (4)
 z = sz zo.
This operation allows the shape of the phantoms to be modified to resemble 
that of the actual patient more closely. It should be noted, however, that all 
measures in a given direction (i.e., vertical or horizontal) are being multiplied 
by the same scaling factor, and phantom shape variability due to, e.g., variability 
in the amount of fat tissue cannot be simulated by this method. An example 
of the height and weight transformation of the phantom is shown in Figure 3. 
This transformation does not have any effect on the coordinate system used for 
entering the x-ray beam geometry: the origin remains at the centre of the base of 
the trunk. The location of the organs will change, and the input coordinates of the 
x-ray beam have to be changed accordingly in order to simulate the irradiation 
of the same body part. 
s
h
hz
=
0
s
h M
h Mxy
= ⋅
⋅
0
0
,
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 (a) (b) (c).
Figure 3. An example of the effect of the patient size transformation. The phantoms 
shown represent 5-year-old patients of height 109.1 cm with various mass: (a) 12.45 kg, 
(b) 19.0 kg, (c) 29.0 kg. The figure shows the body outline and the location of internal 
organs and the skeleton as seen from the front of the phantom.
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4 The Monte Carlo method
Monte Carlo calculation of photon transport is based on stochastic mathematical 
simulation of the interactions between photons and matter (for a review and 
general references on Monte Carlo techniques see, e.g., Andreo 1991). Photons 
are emitted (in a fictitious mathematical sense) from an isotropic point source 
into the solid angle specified by the focal distance and the x-ray field dimensions, 
and followed while they randomly interact with the phantom according to the 
probability distributions of the physical processes that they may undergo: photo-
electric absorption, coherent (Rayleigh) scattering or incoherent (Compton) 
scattering. This chain of interactions forms a so-called photon history. The cross 
sections for the photo-electric interaction, coherent scattering and incoherent 
scattering have been taken from Storm and Israel (1970) and the atomic form 
factors and incoherent scattering functions from Hubbell et al. (1975). Other 
interactions are not considered in PCXMC, because the maximum photon energy 
is limited to 150 keV. At these energies the range of secondary electrons in soft 
tissue is only a fraction of a millimetre, and the energy of the secondary electrons 
is approximated to be absorbed at the site of the photon interaction (except in 
calculating the bone marrow dose, see below). At each interaction point the 
energy deposition to the organ at that position is calculated and stored for dose 
calculation. A large number of independent random photon histories is generated, 
and estimates of the mean values of the energy depositions in the various organs 
of the phantom are used for calculating the dose in these organs. 
Pseudo random numbers are generated by a multiplicative linear 
congruential generator, MLCG(16807, 231-1)  (Vattulainen et al. 1993), and are 
used for sampling the initial photon direction, distance between interactions, 
type of interacting atom, type of interaction and scattering angle (and the 
corresponding energy loss). To improve the precision, the photons are constrained 
not to be absorbed by the photo-electric interaction; instead, the photo-electric 
absorption has been treated by associating a 'weight' to the photons. This weight, 
w, represents the expected proportion of photons that would have survived 
absorption in the preceding interactions, and is reduced in each interaction 
according to the probability of photo-electric absorption (p). At each interaction, 
an energy deposition of w∙p∙E+w∙(1-p)∙DE  is made to the organ where the 
interaction occurs, and the photon weight is reduced to wnew = wold∙(1-p). Here, 
E is the photon energy before the interaction and DE the energy loss in the 
scattering interaction. Each photon is followed until it exits the phantom without 
hitting it again, its energy falls to less than 2 keV (in which case it is forced to 
be absorbed), or until its weight is reduced to less than 0.003. In the last case, 
the photon is subjected to a game of Russian roulette: it is discarded with a 
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probability of 0.75, but if it survives its weight is multiplied by a factor of four. 
Characteristic radiation resulting from the excitation of atoms in the body is 
not simulated, but it is assumed to be absorbed at the primary interaction site. 
There are no heavy elements in the phantoms; the maximum energy of such 
characteristic quanta would be about 4 keV and they would be absorbed near 
the primary interaction site.
The bones of the mathematical phantoms are modelled as a homogeneous 
mixture of mineral bone and organic constituents of the skeleton, including 
active bone marrow. The overall composition of the skeleton is approximated 
as being constant over all bones in the body (see Table IV), but the amount of 
active bone marrow is varied from one part of the skeleton to another and is 
different for phantoms representing different ages (Cristy and Eckerman 1987). 
In reality, active bone marrow is located in small cavities in trabecular bone 
which causes the dose in the bone marrow to be higher than the kerma, due to 
secondary electrons from the bone matrix. This must be taken into account when 
calculating the dose to the active bone marrow. PCXMC calculates the dose in 
both components of the skeleton, the active bone marrow and the rest of skeletal 
material, by dividing the absorbed energy in the whole skeleton into two parts: 
active bone marrow and other constituents of bone (e.g., Rosenstein 1976a). For 
an energy deposition ∆E in a specific skeletal part i from a photon with energy 
E, the part of energy deposited in the active bone marrow in that skeleton part, 
∆EABM, i, is calculated by 
(5)
where mbone, i and mABM, i denote the mass of the skeleton part i, and the mass 
of active bone marrow in that skeleton part, respectively. μen(E)/ρ is the mass-
energy absorption coefficient. The influence of the small cavity size on the dose 
in the active bone marrow is considered by multiplication with a photon energy 
dependent kerma-to-dose conversion factor (or dose enhancement factor), fi (E), 
which increases the active bone marrow dose by a few percents when compared 
to the kerma (Kerr and Eckerman 1985, King and Spiers 1985). The size of the 
bone marrow cavities may vary depending on the age or the anatomical part of 
the skeleton (King and Spiers 1985), but this has not been taken into account in 
PCXMC: the same factor (Figure 4) is used for all bones and all phantom ages. 
The energy deposition in the other constituents of the skeleton (all other bone 
material than active bone marrow) is then ∆E–∆EABM, i. The dose in the active 
bone marrow is calculated as a sum over all energy depositions and all parts of 
the skeleton according to Equation (5), divided by the total mass of active bone 
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marrow. For a discussion of various methods of calculating dose in the active 
bone marrow see the paper of Lee et al. (2006b).
Figure 4. The kerma-to-dose conversion factor for active bone marrow in the lumbar 
vertebra (Kerr and Eckerman 1985). PCXMC uses this curve for all bone marrow sites.
PCXMC calculates the organ doses for monochromatic photons of 10, 20, ..., 150 keV 
energy [or up to an user-defined maximum (which is below 150 keV)] in ten 
different batches of each energy value. This is sufficient, because the absorbed 
energy per photon is a smooth function of photon energy in any organ; the value 
of absorbed energy per photon at other photon energies can be obtained with 
sufficient accuracy by linear interpolation. The final estimate of the absorption 
at each simulated energy value is obtained as the average of these batches, and 
the statistical error is estimated from the standard deviation of these batches. 
The doses and their statistical errors for a practical x-ray spectrum of interest 
are calculated afterwards by another module included in the program. The same 
Monte Carlo data can, therefore, be used for calculating doses for any spectrum 
of interest; such calculations are fast because they do not involve any further 
Monte Carlo simulations. 
The x-ray spectra are calculated according to the theory of Birch and 
Marshal (1979) and are specified in terms of the x-ray tube voltage (kV), the angle 
of the tungsten target of the x-ray tube, and filtration. In the present version of 
the program, the user can simultaneously define two filters of arbitrary atomic 
number and thickness. The filter data are from the compiled x-ray interaction 
data of McMaster et al. (1969). Air kerma is calculated from photon fluence data 
using the conversion coefficients in ICRU (1992b) and Büermann et al. (2006).
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It should be noted that the precision of both the dose estimate and the 
estimate of its statistical error depend on the number of simulated interactions 
in the organ. The precision may be poor even for a large number of simulated 
photon histories if the dose in the organ is low or the organ small. It should 
also be noted that when the number of interactions is small, which is indicated 
by a high value of the statistical error, the estimate has a skewed non-normal 
distribution and the actual statistical errors may be higher than expected on 
the basis of the standard deviation. 
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5 Comparison with other data
The data calculated with PCXMC versions 1.2–1.5 have been earlier compared to 
the organ dose conversion factors calculated in NRPB by Jones and Wall (1985) 
and Hart et al. (1994b, 1996b) and were found to agree well. This agreement 
was to be expected, because also their data were calculated using the phantom 
models of Cristy (1980). Reasonable agreement of PCXMC results has also been 
found in many comparisons with other dose calculations and phantom models or 
dose measurements, e.g., Tapiovaara et al. (1997), Schmidt et al. (2000), Schultz 
et al. (2003) and Helmrot et al. (2007). The agreement with the NRPB data still 
exists for PCXMC 2.0 for most irradiation conditions. Small differences are 
evident in some irradiation conditions, because the composition and density of 
the phantom tissues have been changed and the phantoms have been modified 
from the earlier versions of the program. This is depicted in Figure 5, which 
compares doses in some organs calculated with PCXMC versions 1.5.2 and 2.0 
for a PA-direction photon irradiation of the head and neck. As can be expected 
from the differences in the phantom models, doses to the brain and thyroid are 
higher in the new version, whereas the dose in the muscle tissue is lower. The 
change in the oesophagus model and the change in the composition of active bone 
marrow also result in differences between these program versions. 
Figures 6 and 7 compare organ dose data for two x-ray examinations, adult 
PA chest and paediatric AP abdomen, from PCXMC versions 1.2 and 2.0 and the 
data of NRPB. For the purpose of comparison, the NRPB data below have been 
renormalized to correspond to an air kerma (free-in-air) of 1 Gy. It is seen that 
in these examinations the conversion factors of most organs have not changed 
appreciably from the earlier versions of PCXMC. Exceptions to this are the 
active bone marrow, oesophagus and thyroid, where changes in the composition, 
modelling or surroundings, respectively, have been made. Similar changes can be 
expected also for other organs that have been modified from the earlier version, 
e.g. the breast of the 15-year-old phantom.
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Figure 5. A comparison of  the organ dose conversion  factors calculated by PCXMC 
versions 1.5.2 and 2.0. All doses correspond to an entrance air kerma (free-in-air) of 
1 Gy. Newborn patient, irradiation of the head and neck, PA projection, FSD 100 cm, 
x-ray tube voltage 70 kV, filtration 3 mm Al, 17o x-ray tube anode angle. The error bars 
shown correspond to two standard errors of the data.
Figure 6. A comparison of  the organ dose conversion  factors calculated by PCXMC 
versions 1.2 and 2.0 with the data of Jones and Wall (1985 , NRPB data with error bars) 
and Hart et al. (1994b, NRPB data without error bars). All doses correspond to an incident 
air kerma of 1 Gy. Adult patient, chest examination, PA projection, x-ray tube voltage 
120 kV, filtration 3 mm Al, 17o x-ray tube anode angle, FSD 160 cm. The error bars shown 
correspond to two standard errors of the data.
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Figure 7. A comparison of  the organ dose conversion  factors calculated by PCXMC 
versions 1.2 and 2.0 with the data of Hart et al.  (1996b). All doses correspond to an 
entrance air kerma (free-in-air) of 1 Gy. 1-year-old patient, abdomen examination, AP 
projection, x-ray tube voltage 70 kV, filtration 3 mm Al, 17o x-ray tube anode angle, FSD 
92 cm. The error bars shown correspond to two standard errors of the data.
As was already noted above, the organ doses calculated are strictly valid only for 
the phantoms used for the calculation. To illustrate differences between different 
phantom models, we have compared organ dose conversion data calculated with 
PCXMC to the data of Schlattl et al. (2007) who have calculated dose conversion 
factors for whole body external exposure of photons using voxel phantoms ‘Rex’ 
and ‘Regina’ that are expected to be adopted as the standard human models by 
the ICRP. Figure 8 shows their conversion coefficient from air kerma to effective 
dose as a function of photon energy for total body irradiation from the front 
(AP-direction) and back (PA-direction). The conversion factors of PCXMC have 
been calculated as an average of the effective doses of two adult phantoms which 
have been matched to the height and mass of Rex and Regina. The agreement 
between the data calculated with PCXMC and the data of Schlattl et al. (2007) 
is remarkable in the AP irradiation case, and reasonable in the PA irradiation 
case.
Figure 9 shows the photon energy dependence of the conversion coefficient 
from air kerma to the dose in salivary glands. The data of Schlattl et al. (2007) 
are given for both their phantoms, Rex and Regina, and the data calculated with 
PCXMC are obtained by hermaphrodite phantoms matched to the height and 
mass of Rex and Regina. 
The largest difference between the dose conversion factors of Schlattl 
et al. (2007) and PCXMC are in the doses in bones: the values calculated with 
PCXMC are about 50% larger, depending on the photon energy. This is probably 
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due to the difference in bone modelling. PCXMC uses the homogeneous bone-
approximation whereas the bone model of Schlattl et al consider cortical bone 
and spongiosa separately and calculate the dose in the spongiosa only: the effect 
of the cortical part is to shield the spongiosa, and the dose in the spongiosa is 
reduced. Generally, the organ doses reported in Schlattl et al. (2007) correspond 
to the size-matched phantom data of PCXMC to within about 20%, and are 
sometimes lower and sometimes higher. For some organs the data (e.g., thyroid, 
skin, lungs, female liver and female thyroid) agree notably better, within about 
5–10 % for energies above 20 keV. Typically, the doses in the two different-sized 
phantoms vary less in PCXMC than they do in the data of Schlattl et al. An 
example of typical organ data, the stomach, is shown in Figure 10. 
Figure 8. A comparison of the photon energy dependence of conversion factors from 
air kerma to effective dose. The data of Schlattl et al. (2007) are represented as curves 
and data points  calculated with PCXMC 2.0 are marked with o  and ×. Whole body 
irradiation of the phantoms with monochromatic and unidirectional photons. PCXMC 
data calculated as the average of doses in phantoms matched to the size of the reference 
phantoms of Schlattl et al. 
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Figure 9. A comparison of the photon energy dependence of conversion factors from 
air  kerma  to  the dose  in  salivary glands. Continuous  curve:  ‘Regina’  (Schlattl  et  al. 
2007); points marked with o: PCXMC data for a phantom matched in size with ‘Regina’. 
Broken  curve:  ‘Rex’  (Schlattl  et  al.  2007);  points marked with ×:  PCXMC data  for  a 
phantom matched in size with ‘Rex’. Whole body AP irradiation of the phantoms with 
monochromatic, unidirectional photons. 
Figure 10. A comparison of the photon energy dependence of conversion factors from air 
kerma to the dose in the stomach. Continuous curve: ‘Regina’ (Schlattl et al. 2007); points 
marked with o: PCXMC data for a phantom matched in size with ‘Regina’. Broken curve: 
‘Rex’ (Schlattl et al. 2007); points marked with ×: PCXMC data for a phantom matched 
in size with  ‘Rex’. Whole body AP  irradiation of  the phantoms with monochromatic, 
unidirectional photons.
Salivary glands
0
0,2
0,4
0,6
0,8
1
1,2
0 20 40 60 80 100 120 140 160
Energy (keV)
G
y/
G
y
Stomach
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
0 20 40 60 80 100 120 140 160
Energy (keV)
G
y/
G
y
35
STUK-A231
The usability of the phantom size modification feature of PCXMC has been 
demonstrated in an extreme case by Smans et al. (2008) who calculated doses in 
two premature babies with weights of 590 g and 1910 g. The differences between 
the results of PCXMC and the Monte Carlo software that was used in their work 
were explained by the differences in the phantom models and the difficulty to 
place an x-ray field similarly in different phantoms. The dose conversion values in 
that paper were made with PCXMC 1.5.2. We have repeated the calculations with 
PCXMC 2.0, and obtained essentially the same results as were reported in the 
paper of Smans et al. (2008); in this case the differences between the two PCXMC 
versions are caused mainly by the changes in the densities and composition of the 
phantom tissues. The data of Smans et al. (2008) and the newly calculated results 
for the chest AP examination of the smaller phantom are shown in Table V. In 
order to demonstrate the remarkable effect of field location in such comparisons, 
the table also includes PCXMC 2.0 data calculated with a slightly larger field 
and a downward displacement of the x-ray field by 0.5 cm.
Similar organ dose differences between computational and voxel phantoms 
have also been seen in the papers of Staton et al. (2003), Lee et al. (2006c) and 
Pazik et al. (2007); dose differences of the same order are obtained also in doses 
of different voxel phantoms (Zankl et al. 2002, Schlattl et al. 2007).
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Table V. Comparison of  the organ dose conversion data  for a chest AP examination 
calculated by Smans et al (2008) with data calculated with PCXMC 2.0 for a premature 
baby of 590 g weight. The last column shows data calculated for the case of a slightly 
larger and slightly lower located x-ray field. X-ray tube voltage 65 kV, total filtration 
4 mm Al, FSD 105 cm. 
Organ or tissue Smans et 
al. (2008)
7×5 cm2 field
voxel phantom
(Gy/Gy)
PCXMC 1.5
7×5 cm2 field
(Gy/Gy)
PCXMC 2.0
7×5 cm2 
field
(Gy/Gy)
PCXMC 2.0
7×6 cm2 field 
0.5 cm lower
(Gy/Gy)
Active bone 
marrow
0.13 0.11 0.15 0.18
Adrenals 0.06 0.17 0.20 0.40
Brain 0.01 0.00 0.01 0.01
Colon 0.01 0.01 0.01 0.03
Heart 0.89 0.87 0.94 0.96
Kidneys 0.02 0.04 0.04 0.14
Liver 0.28 0.19 0.23 0.55
Lungs 0.95 0.82 0.82 0.84
Oesophagus 0.54 0.45 0.51 0.58
Pancreas 0.08 0.10 0.11 0.63
Skeleton 0.50 0.74 0.66 0.77
Skin 0.15 0.16 0.17 0.20
Small intestine 0.02 0.01 0.02 0.03
Spleen 0.47 0.11 0.13 0.45
Stomach 0.22 0.11 0.14 0.51
Testicles 0.00 0.00 0.00 0.00
Thymus 0.93 1.05 1.05 1.06
Thyroid 0.09 0.09 0.08 0.08
Urinary bladder 0.00 0.00 0.00 0.01
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6 Risk assessment
Many mathematical models have been developed for estimating the cancer 
risk resulting from an exposure to ionising radiation. One such set of models 
is developed by the BEIR (Committee on the Biological Effects of Ionizing 
Radiations, BEIR 2006). The BEIR VII committee has derived risk models both 
for cancer incidence and for cancer mortality. The models take into account the 
cancer site, sex, age at the exposure and attained age. Presently, low dose rates 
and small doses are believed to yield a relatively lower cancer risk compared to 
high dose rates and large doses. This reduction in risk is accounted for by the 
dose and dose rate reduction factor (DDREF). 
Age-dependent mortality rates are used for subsequent assessment of 
lifetime cancer risk. Risk models are presented for leukaemia, solid cancers in 
some organs and for all solid cancers combined. For all these cancer types the 
BEIR VII committee derived absolute and relative risk models: in the absolute 
risk model excess cancer risk from radiation is independent of the background 
cancer risk (i.e., cancers from other causes than radiation) and in the relative 
risk model the radiation risk is proportional to the background cancer risk. The 
BEIR VII committee combines these models in their final risk estimate. 
Many factors, e.g., limitations in epidemiologic data for radiation-induced 
cancer, contribute to the uncertainty of risk estimation. The BEIR VII committee 
suggests that the risk estimates should be regarded with a healthy scepticism, 
placing more emphasis on the magnitude of the risk. The committee estimates 
that the excess cancer mortality due to radiation can be estimated within a factor 
of two (at 95% confidence level). For leukaemia the corresponding factor is four. 
For individual solid cancer sites the risk estimation may have large uncertainties, 
up to an order of magnitude or more (BEIR 2006).
For solid cancers the models of the excess relative and absolute risk (ERR 
and EAR, respectively) at attained age t are of the form (BEIR 2006)
(6)
where e is age at exposure in years, e* = (e - 30 a)/10 a when e < 30 a, and e* is 
equal to zero for e ≥ 30 a for other solid cancers than breast cancer and thyroid 
cancer. For these two cancers, e* = (e - 30 a)/10 a for all values of e.3) Attained 
age (in years) is t, and D is the organ or tissue equivalent dose. βS, g and h are 
fitting parameters of the model. For leukaemia the ERR and EAR models are 
of the form
ERR or EAR a( , , ) ( , , ) exp / ,*t e D t e D D e tS= ( ) ( )b g h60
3) This difference of the risk models of the female breast and the thyroid from the risk models 
of other organs was not properly taken into account in PCXMC version 2.0.0. It has been cor-
rected in version 2.0.1.
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(7)
where t - e is the time elapsed after the exposure and D is the equivalent dose 
in bone marrow. q , d and j are fitting parameters. The site-specific EAR values 
in the BEIR VII model consider cancer incidence. Therefore, in order to estimate 
cancer mortality, the incidence values are scaled with the ratio of the sex- and 
age-specific mortality and incidence rates for the site-specific cancer in question 
(BEIR 2006).
BEIR (2006) does not provide risk estimates for all organs and tissues. 
The risk of cancer death from other solid cancers than in those organs that are 
included in the risk models is estimated in PCXMC using BEIR’s model for 
“other solid cancers”. The related cancer statistics is taken as the statistics for 
all solid cancers from which the separately considered solid cancer types have 
been subtracted. It is not self-evident how the dose corresponding to these “other 
solid cancers” should be determined when the dose distribution in the body is 
not uniform. If one would use the average dose of all the organs involved, this 
dose would correspond mainly to the dose in muscle tissue because of its large 
mass, and this would presumably be not reasonable. In PCXMC, therefore, a 
weighted average dose in the other organs and tissues (“weighted remainder”) 
has been used. This weighted average dose used in the risk estimation of “other 
solid cancers” is calculated as the weighted average dose in organs and tissues 
that are not given a direct risk estimate. The weighting is done with the tissue 
weighting factors of ICRP Publication 103, renormalized such that their sum is 
equal to one. In effect, this involves the assumption that the relative sensitivities 
of these organs are in proportion to the tissue weighting factors of ICRP 103.
The cancer risks are non-zero only after a latency period. The BEIR VII 
committee assumes that solid cancers have a latency period of 5 years. For 
leukaemia the latency period is 2 years. These values are used in PCXMC as a 
default.
The excess risk values are the basis of the lifetime risk estimates. The 
lifetime risks can be assessed with various quantities. PCXMC uses three 
different quantities:
•	 Risk	of	exposure-induced	death	(REID)
•	 Loss	of	life	expectancy	(LLE)
•	 Loss	of	life	expectancy	per	radiation	induced	fatal	cancer	(LLE/REID).
ERR or EAR( , , ) ( , , ) ( )
*
t e D t e D D D
e
S= + ⋅b q
g
1
                   exp + −( ) + −( ) d jlog ( ) / log ( ) /*t e e t e25 25a a
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The definitions of these quantities are (Thomas et al. 1992)
(8)
and
(9)
Here, μc(t | e, D) is the mortality rate at age t due to death cause c, given that 
the subject was alive at the age of exposure e and the corresponding dose at that 
age was D. In the excess relative risk model
(10)
where μc(t) is the background mortality rate related to the death cause c. In the 
excess absolute risk model
(11)
S(t | e, D) is the conditional probability that the subject is alive at age t, given 
a dose D at the age e. For an unexposed subject the probability of surviving 
to age t is S(t | e). These conditional survival functions are calculated from 
mortality statistics, cancer mortality rates and, for S(t | e, D), the risk models. 
Specifically,
(12)
where μ(t | e, D) is the death rate for all causes combined. Thus, the software 
accounts for the reduction in S caused by the radiation exposure, and the site-
specific REID estimates for different cancers can be added. The sum obtained 
reflects the total risk from the exposure in question. The lower limit in the 
integrals (8) and (9) is t=e+l, where l is the latency period in years. In PCXMC, 
the upper integration limit has been set to 120 years instead of infinity in these 
equations.
The concept of REID originates from cohort analysis techniques: death 
rates in the exposed and in the unexposed cohorts are compared. A null hypothesis 
corresponds to a statistically negligible difference between the two groups. A 
positive REID value indicates excess deaths in the exposed cohort. 
In the risk assessment model of BEIR the REID-values of relative and 
absolute risk models are combined and they are given the weights of 0.7 and 0.3, 
respectively [the weighting is done on a logarithmic scale as suggested by BEIR 
(2006)]. For the lung cancer these weights are reversed. For the breast cancer 
REIDc c ce D t e D t S t e D dt( , ) ( | , ) ( ) ( | , )= −[ ]
∞
∫ m m
t
LLE( , ) ( | ) ( | , ) .e D S t e dt S t e D dt= −
∞∞
∫∫
tt
m mc ct e D t e D t( | , ) ( , , ) ( ),= +[ ]1 ERRc
m mc ct e D t e D t( | , ) ( , , ) ( ).= +EARc
S t e D x e D dx
e
t
( | , ) exp ( | , ) ,= −







∫m
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only the absolute model is used and for the thyroid cancer only the relative risk 
model is used. The DDREF division is done after the weighting.
The loss of life expectancy (LLE) is the difference between the expectation 
of life for a person exposed at age e and of an unexposed person who was alive 
at that age. LLE/REID describes the average length of life lost per excess cancer 
death. More information on the quantities can be found in Thomas et al. (1992) 
and Vaeth and Pierce (1990). These quantities have not been considered in BEIR 
(2006). Therefore, PCXMC estimates LLE using the relative risk model only and 
does not use the DDREF concept in calculating it.
The BEIR VII -committee simplified the definition of REID by replacing 
S(t | e, D) by S(t | e). The resulting risk estimate was called the lifetime 
attributable risk (LAR) (BEIR 2006). Also, the concept of excess lifetime risk 
(ELR) is sometimes used in the literature. For practical purposes, at typical dose 
levels encountered in x-ray diagnostics, REID, ELR and LAR can be interpreted 
to present the excess radiation-induced cancer risk. Their numerical values are 
close enough to be interpreted identical considering the uncertainties involved 
in the models.
The BEIR VII -committee recommends to use the dose and dose rate 
reduction factor value DDREF = 1.5 for solid cancers and DDREF = 1 for 
leukaemia. As a default, these values are used also in PCXMC. If the equivalent 
doses are large (several tens or hundreds of mSv), the risk estimates should be 
regarded with care: it might be more appropriate to use DDREF = 1 also for 
solid cancers in such cases. This can be achieved by multiplying the solid cancer 
REID estimates of PCXMC by 1.5. Moreover, the risk models describe only the 
stochastic effects of ionising radiation – if deterministic effects are possible, the 
risk estimates should be interpreted carefully.
The necessary input data for the calculation include the sex-specific 
mortality and cancer incidence rates. In the default data sets in PCXMC these 
data are mostly given in five year intervals and are assumed to be constant 
within the age intervals. The Finnish mortality data are from Statistics Finland 
databank (www.tilastokeskus.fi) and the cancer mortality and incidence data 
are from Finnish Cancer Registry (www.cancerregistry.fi), retrieved on  March 
20, 2007. The Euro-American and Asian mortality and cancer incidence data 
are from ICRP publication 103 (ICRP, 2007). Chronic lymphocytic leukaemia 
is believed to be unrelated to radiation exposure. Therefore it is excluded from 
the ICRP 103 leukaemia mortality data. The Finnish mortality and incidence 
data include all leukaemia types, leading to a slightly overestimated leukaemia 
risk. This overestimation is much less than the uncertainty present in the risk 
model for leukaemia.
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Mortality statistics for Euro-American males (ICRP 2007) are illustrated 
in Figure 11. Examples of risk calculations for females are shown in Tables VI 
and VII. The values from BEIR (2006), Table 12D-2, are in reasonable agreement 
with the data calculated using PCXMC with American cancer data (retrieved 
from seer.cancer.gov) and Euro-American mortality data (ICRP 2007). Therefore, 
the implementation of the risk model of BEIR in PCXMC can be considered valid. 
The differences between the REID values calculated with PCXMC (for other 
regional statistics) and those in BEIR (2006) just reflect the differences in the 
regional mortality and cancer statistics used in PCXMC and the American data 
used in BEIR (2006). 
Figure 11. Risks of death (in percent per year) for Euro-American males (ICRP 2007). 
Risks of death for all causes combined (black line), for all cancers combined (grey line) 
and for lung cancer (light grey line) are shown for five year age intervals. The highest 
age group covers ages 90–120 years.
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Table VI. The excess number of deaths per  105  females  assuming various mortality 
statistics. A single dose of 0.1 Gy to stomach is assumed. The risk estimates have been 
adjusted by a DDREF of 1.5. The BEIR VII values (second column) are from Table 12D-2 
of BEIR (2006). The American data (third column) were calculated with PCXMC using 
American cancer mortality data,  retrieved from seer.cancer.gov (not  included  in  the 
PCXMC distribution), and Euro-American mortality statistics from the ICRP publication 
103. These data are presented here in order to compare PCXMC-calculated data with 
those given in BEIR VII. The last three columns use mortality and cancer statistics which 
are readily included in the data files of PCXMC.
Number of excess deaths
Age at 
exposure 
(years)
BEIR VII American 
statistics
(PCXMC)
Asian 
statistics
(PCXMC)
Euro-
American 
statistics
(PCXMC)
Finnish 
statistics
(PCXMC)
0 57 61 166 83 104
10 41 44 119 60 74
20 29 31 85 43 54
30 21 22 60 30 38
40 20 21 57 30 37
50 19 20 54 28 35
60 16 18 47 26 31
70 13 15 38 22 25
80 8 11 24 16 17
Table VII. The excess number of deaths per 105  females assuming various mortality 
statistics. A single dose of 0.1 Gy to breasts is assumed. The risk estimates have been 
adjusted by a DDREF of 1.5. The BEIR VII values are from Table 12D-2 of BEIR (2006). 
The American data (third column) were calculated with PCXMC using American cancer 
mortality data, retrieved from seer.cancer.gov (not included in the PCXMC distribution), 
and Euro-American mortality statistics from the ICRP publication 103. These data are 
presented here in order to compare PCXMC-calculated data with those given in BEIR 
VII. The last three columns use mortality and cancer statistics which are readily included 
in the data files of PCXMC.
Number of excess deaths
Age at 
exposure 
(years)
BEIR VII American 
statistics
(PCXMC)
Asian 
statistics
(PCXMC)
Euro-
American 
statistics
(PCXMC)
Finnish 
statistics
(PCXMC)
0 274 287 338 363 302
10 167 173 203 219 182
20 101 104 122 132 109
30 61 62 73 79 66
40 35 36 43 46 39
50 19 20 24 26 22
60 9 11 12 14 12
70 5 5 6 7 6
80 2 3 4 3 3
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